Live tape
Top 8, mentions 7d10,595TSLA2,251 mentions▲ +0.05GOOGL1,489 mentions▲ +0.04CRWV1,422 mentions▲ +0.03SPCX1,338 mentions▲ +0.07NVDA1,184 mentions▲ +0.07QQQ1,154 mentions▲ +0.05NBIS915 mentions▲ +0.06META842 mentions▲ +0.05

Equity · Healthcare

TBPH

NASDAQ

Theravance Biopharma (TBPH)

$16.94 −0.24% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close)
Price · Chart

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for TBPH to draw a line in its place.

Track this symbol on TradingView TradingView chart
Market cap $879.5M
P/E (TTM) 16.8
52-week range $11 – $21
Avg volume 244.2K

as of Jul 17, 2026

Theravance Biopharma (TBPH) insider trades

SEC Form 4 · last 90 days · newest reported trade 15 Sep 2026

In the 90 days to 21 Oct 2026, Theravance Biopharma insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 11 Nov 2025, show no open-market purchase.

Open-market buys 0
Open-market sells 1
Net sold $227K
Non-trade filings 16
Date Insider Type Shares Value
15 Sep 2026 Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS Sell 13,314 $227K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
23 Sep 2026 Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS Other 213,476
23 Sep 2026 GRAY SUSANNAH Director Other 48,146
23 Sep 2026 Grimaud Brett A. SVP, GEN COUNSEL AND SECRETARY Other 355,168
23 Sep 2026 MITCHELL DEAN J Director Other 97,213
23 Sep 2026 Miller Aine SVP, DEV & HEAD OF IRE OFFICE Other 189,826
23 Sep 2026 O'Connor Donal Director Other 80,213
23 Sep 2026 PAKIANATHAN DEEPIKA Director Other 64,074
23 Sep 2026 Sawaf Aziz SVP & CHIEF FINANCIAL OFFICER Other 336,841
23 Sep 2026 Smaldone Alsup Laurie Director Other 80,989
23 Sep 2026 Winningham Rick E CHIEF EXECUTIVE OFFICER Other 1,726,989
23 Sep 2026 Weiss Asset Management LP Other 7,457,060 $126.77M
20 Aug 2026 Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS Tax withheld 5,667 $96K

Showing the 12 most recent of 16 compensation filings in this window. The figures above count all of them.

Theravance Biopharma (TBPH) reported financials

SEC EDGAR XBRL SEC EDGAR

Theravance Biopharma reported revenue of $107.5M for the fiscal year ended 31 Dec 2025. Net income over the same period was $105.9M.

Figure Reported Period
Revenue $107.5M 31 Dec 2025 fiscal year
Net income $105.9M 31 Dec 2025 fiscal year
Diluted EPS $2.06 31 Dec 2025 fiscal year
Total assets $469.8M 30 Jun 2026 at period end
Total equity $289.7M 30 Jun 2026 at period end

Theravance Biopharma (TBPH) earnings

SEC EDGAR

Theravance Biopharma last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$0.11; no next date is announced in SEC filings yet.

Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$0.11 —
31 Mar 2026 Q1 2026 −$0.10 —
31 Dec 2025 FY 2025 $1.15 —
30 Sep 2025 FY 2025 $0.07 —
30 Jun 2025 FY 2025 $1.08 —
31 Mar 2025 Q1 2025 −$0.27 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

Theravance Biopharma (TBPH) institutional holders (13F)

SEC Form 13F SEC EDGAR

9 of the 45 institutional funds we track reported a Theravance Biopharma position for the quarter ended 30 Jun 2026 — a combined $59.9M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Two Sigma Investments Held (±25%) −2.6% shares 1,225,587 $20.8M
D. E. Shaw & Co. Held (±25%) +24.2% shares 1,185,390 $20.2M
Citadel Advisors Added +488.5% shares 506,668 $8.6M
Marshall Wace Held (±25%) +18.8% shares 188,748 $3.2M
Renaissance Technologies Held (±25%) +20.6% shares 154,318 $2.6M
Millennium Management New position 115,403 $2.0M
Tudor Investment Corp Trimmed −49.7% shares 60,425 $1.0M
AQR Capital Management Added +74.8% shares 47,820 $813K
Man Group Held (±25%) −3.5% shares 40,613 $690K

Theravance Biopharma (TBPH) fails-to-deliver

SEC CNS data SEC

On 23 Sep 2026, 55 shares of Theravance Biopharma failed to deliver (about $937).

Settlement date Shares failed Notional % of shares out
23 Sep 2026 55 $937 <0.001%
21 Sep 2026 1,370 $23K 0.003%
10 Sep 2026 10 $171 <0.001%

Congressional trades in Theravance Biopharma (TBPH)

STOCK Act disclosures House disclosures

The most recent congressional trade disclosed in Theravance Biopharma is a sale by George Whitesides (house, CA), dated 24 Mar 2025.

Date Member Type Amount
24 Mar 2025 filed 23 Apr 2025 George Whitesides house · Democrat–CA Sale $15K–$50K

Theravance Biopharma (TBPH): frequently asked questions

From live data

Have Theravance Biopharma insiders bought or sold shares recently?

In the 90 days to 21 Oct 2026, Theravance Biopharma insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 11 Nov 2025, show no open-market purchase. A further 16 filings were grants, awards, gifts or exercises rather than open-market trades.

How many institutions hold Theravance Biopharma?

9 of the 45 institutional funds we track reported a Theravance Biopharma position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has Theravance Biopharma had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for Theravance Biopharma is dated 23 Sep 2026, when 55 shares failed to deliver.

When did Theravance Biopharma last report earnings?

Theravance Biopharma last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$0.11; no next date is announced in SEC filings yet.

What exchange is Theravance Biopharma listed on?

Theravance Biopharma trades on NASDAQ under the ticker TBPH.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SEC EDGARValuation computed from SEC EDGAR filings